[關(guān)鍵詞]
[摘要]
為提高抗病毒藥物在新型冠狀病毒肺炎（COVID-19）患者尤其是需要多藥聯(lián)合患者中的合理性和安全性，結(jié)合《新型冠狀病毒肺炎診療方案（試行第七版）》提到的抗病毒藥物，通過查閱文獻、搜集各抗病毒藥物說明書和MCDEX合理用藥信息支持系統(tǒng)的相關(guān)信息，總結(jié)這些抗病毒藥物的臨床藥動學(xué)特征、藥物相互作用及不良反應(yīng)信息，提出合理的用藥監(jiān)護建議。從藥動學(xué)和藥物相互作用角度加強抗病毒藥物在COVID-19患者中的用藥監(jiān)護，可提高藥物使用安全性，保障患者的合理用藥。
[Key word]
[Abstract]
To improve the rationality and safety of anti-novel coronavirus drugs in patients with corona virus disease 2019 (COVID-19), especially those with underlying diseases. Based on antiviral drugs mentioned in "COVID-19 Treatment Plan (Trial Version 7)", the clinical pharmacokinetic characteristics, drug interaction and adverse reaction information of these antiviral drugs were summarized by consulting the literature, collecting the information from the antiviral drugs instructions and the information from MCDEX rational drug use system. And the reasonable suggestions for drug monitoring were summarized and put forward. From the perspective of pharmacokinetics and drug interaction, the monitoring of antiviral drugs and combined drugs in patients with COVID-19 should be strengthened, which will be helpful for safe and rational use of these drugs.
[中圖分類號]
R978
[基金項目]
國家自然科學(xué)基金資助項目（81803789、81704023、81602535）；武漢大學(xué)人民醫(yī)院引導(dǎo)基金資助項目（RMYD2018M79）
